The ISDC Issues Annual Report on Federal Suspension and Debarment Activities and Trends
Client Alert | 1 min read | 04.19.22
On April 18, 2022, the Interagency Suspension and Debarment Committee (ISDC) issued its annual report to Congress on federal suspension and debarment activities for Fiscal Year (FY) 2020. During FY 2020, the ISDC continued to focus on promoting the fundamental fairness of the suspension and debarment process, increasing transparency and consistency, enhancing suspension and debarment practices and alternatives, and encouraging more effective compliance and ethics programs by government contractors and nonprocurement participants. The ISDC also formed a subcommittee to provide recommendations and assistance to the Federal Acquisition Regulatory (FAR) Counsel drafting team to better align suspension and debarment procedures in the FAR with the Nonprocurement Common Rule (NCR).
Despite the COVID-19 pandemic, the report notes that the number of debarments in FY 2020 increased from FY 2019. However, suspensions, proposed debarments, and referrals of new matters all decreased, which was a result of several factors, including delays in mail service, travel restrictions, and postponements in court proceedings. With the exception of pre-notice letters, the metrics also indicate that agencies relied more heavily on alternatives to suspension and debarment, such as administrative agreements, voluntary exclusions, post-notice engagements, and declinations. Notably, the agencies that executed alternatives to suspension and debarment varied from FY 2019, demonstrating that the government applies administrative remedies based on the particular facts presented in each case.
Contacts
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions